Keyword: Blueprint Medicines
The backloaded, $535 million deal comes months after Ipsen paid $1 billion to buy Clementia Pharmaceuticals for a drug against the same disease.
Frontier Medicines launched with $67 million and a mission to find drug-binding pockets on previously undruggable proteins.
Blueprint Medicines’ BLU-667 shrank tumors in 60% of a difficult-to-treat group of lung cancer patients, teeing it up for a 2020 filing.
KSQ Therapeutics hired biopharma veteran Beni Wolf, M.D., Ph. D as its chief medical officer.
Early data showed that Blueprint's RET inhibitor and AstraZeneca’s Tagrisso could potentially beat treatment resistance in NSCLC patients.
The drug shrunk the tumors of most patients in the trial, raising hopes it can become a new treatment option for patients with RET-altered cancers.
Blueprint's data shows its BLU-667 caused some tumor shrinkage in 84% of patients with lung or thyroid cancer.
The deal will see Thermo Fisher validate and seek approval for a test to identify RET fusions in non-small cell lung cancer patients.
Here's a FierceBiotech Radio episode about the Battle of the Biotech Bands, ahead of the podcast's relaunch in 2018.
The rejig sees Alexion scrapping deals with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma as it seeks to focus its R&D.